Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 2734 • 2019 ACR/ARP Annual Meeting
Signaling Lymphocytic Activation Molecule Family (SLAMF) Receptors Deregulation Is Implicated in the Altered Function of NK Cells in Systemic Lupus Erythematosus
Morgane Humbel ¹, Florence Bellanger ¹, Craig Fenwick ², Alice Horisberger ³, Camillo Ribi ³ and Denis Comte¹, ¹Service of Immunology and Allergy, Lausanne University Hospital and University of Lausanne, Epalinges, Vaud, Switzerland, ²Service of Immunology and Allergy, Lausanne University Hospital and University of Lausanne, Epalinhes, Vaud, Switzerland, ³Service of Immunology and Allergy, Lausanne University Hospital and University of Lausanne, Lausanne, Vaud, Switzerland
Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystemic autoimmune disease characterized by quantitative and qualitative deficiencies of immune cells. Natural killer (NK) cells are innate…
Abstract Number: 2864 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Intravenous Belimumab in Children with Systemic Lupus Erythematosus: An Across-Trial Comparison with the Adult Belimumab Studies
Antonio Nino¹, Damon L Bass ², Gina Eriksson ¹, Anne Hammer ¹, Beulah Ji ³, Holly Quasny ⁴ and David Roth ⁵, ¹GlaxoSmithKline, Collegeville, ²GlaxoSmithKline, Collegeville, PA, ³GSK, Uxbridge, Middlesex, United Kingdom, ⁴GlaxoSmithKline, Research Triangle Park, ⁵GSK, Collegeville, PA
Background/Purpose: Belimumab (BEL) is the first treatment approved for children with systemic lupus erythematosus (SLE) from 5 years of age and older.1 This approval was…
Abstract Number: 95 • 2019 ACR/ARP Annual Meeting
IL-21-mediated Suppression of STAT5 Phosphorylation Underlies Treg Depletion and Dysfunction in SLE
Hiroshi Kato¹ and Andras Perl ¹, ¹SUNY Upstate Medical University, Syracuse, NY
Background/Purpose: IL-21 activates mechanistic target of rapamycin (mTOR) complexes 1 and 2 which in turn block regulatory T (Treg)-cell differentiation and function in patients with…
Abstract Number: 674 • 2019 ACR/ARP Annual Meeting
Affordability Concerns Prevalent Among Patients with Systemic Lupus Erythematosus (SLE)
Kimberly DeQuattro¹, Laura Trupin ¹, Patricia Katz ¹, Stephanie Rush ¹, Louise Murphy ², Maria Dall'Era ¹ and Jinoos Yazdany ³, ¹University of California, San Francisco, San Francisco, CA, ²Centers for Disease Control and Prevention, Division of Population Health, Atlanta, ³UCSF Division of Rheumatology, San Francisco, CA
Background/Purpose: Among rheumatologic conditions, SLE is associated with very high healthcare and out of pocket costs. Little is known about patients’ concerns regarding costs of…
Abstract Number: 896 • 2019 ACR/ARP Annual Meeting
Hydroxychloroquine Use and Cardiovascular Events Among Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis
April Jorge¹, Na Lu ², Hyon K. Choi ¹, John Esdaile ³, Diane Lacaille ⁴ and J. Antonio Avina-Zubieta ⁵, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hosptial, Boston, MA, ³Arthritis Research Canada and the University of British Columbia, Richmond, BC, Canada, ⁴Arthritis Research Canada and University of British Columbia, Vancouver, BC, Canada, ⁵Arthritis Research Canada and the University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Hydroxychloroquine (HCQ) is near-universally recommended for patients with SLE and is often used in the treatment of RA. Use of HCQ has been associated…
Abstract Number: 1091 • 2019 ACR/ARP Annual Meeting
Risk of Preterm Birth by Timing of Lupus Diagnosis Among Women in the Georgia Lupus Registry
Meghan Angley¹, Penelope P. Howards ¹, Cristina Drenkard ¹ and S Sam Lim ¹, ¹Emory University, Atlanta, GA
Background/Purpose: Women with systemic lupus erythematosus (SLE) are at a greater risk of having a preterm birth than the general population. Most studies examine preterm…
Abstract Number: 1559 • 2019 ACR/ARP Annual Meeting
Routine Clinical Pathology Measurements Are Predictive of the Risk of Organ Damage Accrual in SLE
Eric Morand¹, Kevin Zhang ¹, Sarah Boyd ¹, Francois Petitjean ¹, Alberta Hoi ², Rachel Koelmeyer ¹ and Hieu Nim ¹, ¹Monash University, Melbourne, Victoria, Australia, ²School of Clinical Sciences, Monash University, Meloburne, Victoria, Australia
Background/Purpose: Prevention of permanent organ damage, a major predictor of morbidity and mortality, is a key goal in the treatment of SLE. Physician-measured disease activity…
Abstract Number: 1603 • 2019 ACR/ARP Annual Meeting
Stroke Clusters in SLE by Lupus Autoantibodies
Michelle Petri¹ and Daniel Goldman ², ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Stroke is the most common arterial thrombotic event in SLE. It is known to be associated with antiphospholipid antibodies, but clinicians have additional concern…
Abstract Number: 1761 • 2019 ACR/ARP Annual Meeting
The Prospective Open Label Preventive Approach to Congenital Heart Block with Hydroxychloroquine (PATCH) Study Demonstrates a Reduction in the Recurrence Rate of Advanced Block
Peter Izmirly¹, Mimi Kim ², Nathalie Costedoat-Chalumeau ³, Deborah Friedman ⁴, Amit Saxena ⁵, Joshua Copel ⁶, Rebecca Cohen ¹, Mala Masson ¹, Tishaun Middleton ¹, Kimberly Robins ¹, Robert Clancy ¹ and Jill Buyon ¹, ¹NYU School of Medicine, New York, ²Albert Einstein College of Medicine, Bronx, NY, ³Cochin University Hospital, Paris, France, ⁴New York Medical College, Valhalla, ⁵New York University School of Medicine, New York, NY, ⁶Yale School of Medicine, New Haven
Background/Purpose: Based on encouraging bench to bedside results including experimental evidence supporting Toll-like receptor signaling in the pathogenesis of CHB, a case control study demonstrating…
Abstract Number: 2025 • 2019 ACR/ARP Annual Meeting
Ancestry Influences the Gene Expression Profile in Systemic Lupus Erythematosus and Contributes to Transcriptomic Heterogeneity in Lupus Patients
Michelle Catalina¹, Prathyusha Bachali ², Anthony Yeo ³, Nicholas Geraci ², Michelle Petri ⁴, Amrie Grammer ² and Peter Lipsky ², ¹AMPEL BioSolutions, LLC, harvard, MA, ²AMPEL BioSolutions, LLC, Charlottesville, VA, ³Rilite Foundation, Charlottesville, VA, ⁴Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a complex autoimmune disease with both sex and ancestral bias. Gene expression analysis has revealed complex heterogeneity between SLE…
Abstract Number: 2285 • 2019 ACR/ARP Annual Meeting
Higher Than Expected Rates of Adverse Pregnancy Outcomes in Patients with Systemic Lupus Erythematosus from Three Tertiary Care Centers
Ashley Blaske¹, Amanda Eudy ², Katie Kirchoff ³, Jim Oates ⁴, Megan Clowse ² and April Barnado ¹, ¹Vanderbilt University Medical Center, Nashville, TN, ²Duke University, Durham, ³Medical University of South Carolina, Charleston, SC, ⁴Division of Rheumatology & Immunology/Medical University of South Carolina, Charleston, SC
Background/Purpose: Prospective cohort studies of pregnancies managed by experts demonstrate that up to 30% of systemic lupus erythematosus (SLE) pregnancies result in preterm birth. We…
Abstract Number: 2535 • 2019 ACR/ARP Annual Meeting
Identifying Subgroups of SLE Patients with Differential Responses to a BLyS Inhibitor: Application of a Machine Learning Algorithm to Clinical Trial Data
Mimi Kim¹, Kith Pradhan ¹, Peter Izmirly ², Kenneth Kalunian ³, Leslie Hanrahan ⁴ and Joan Merrill ⁵, ¹Albert Einstein College of Medicine, Bronx, NY, ²New York University School of Medicine, New York, ³University of California at San Diego, San Diego, ⁴Lupus Foundation of America, Washington DC, ⁵Oklahoma Medical Research Foundation, Oklahoma City
Background/Purpose: Given the heterogeneity of systemic lupus erythematosus (SLE), the effect of any intervention is expected to vary. The ability to identify those most and…
Abstract Number: 2735 • 2019 ACR/ARP Annual Meeting
Response Gene to Complement -32 Exerts Proinflammatory and Profibrotic Effects in Immune Complex Gediated Glomerulonephritis
Vinh Nguyen ¹, Alexandru Tatomir ², Horea Rus ³, Cinthia Drachenberg ¹, John Papdimitriou ¹, Tudor Badea ⁴, Irina Luzina ⁵ and Violeta Rus¹, ¹Univ of Maryland Sch of Medicine, Baltimore, MD, ²Univ of Maryland Sch of Medicine, Baltimore, ³Univ of Maryland Sch of Med and VAMHCS, Baltimore, MD, ⁴NIH, NEI, Bethesda, MD, ⁵Univ of Maryland Sch of Med AND VAMHCS, Baltimore
Background/Purpose: Response Gene to Complement (RGC)-32 is a cell cycle regulator widely expressed in normal tissues, multiple tumors and a variety of cell lines. RGC-32…
Abstract Number: 2867 • 2019 ACR/ARP Annual Meeting
Nocturnal Blood Pressure Dipping as a Marker of Endothelial and Cardiac Function in Pediatric-onset Systemic Lupus Erythematosus
Joyce Chang¹, Taylor Goldberg ¹, Sarah McGuire ¹, Lindsay Waqar ¹, Kevin Meyers ¹, Laura Mercer-Rosa ¹, Pamela F. Weiss ¹ and Andrea Knight ², ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²Division of Rheumatology, The Hospital for Sick Children, Department of Paediatrics, University of Toronto, Toronto, ON, Canada
Background/Purpose: There is a need for clinically useful measures of cardiovascular (CV) risk in pediatric-onset SLE (pSLE). Nocturnal blood pressure (BP) non-dipping (loss of the…
Abstract Number: 98 • 2019 ACR/ARP Annual Meeting
Selective Induction of Functional Regulatory T-Cells in Healthy Volunteers by NKTR-358, a Novel IL-2 Conjugate Treg Stimulator, in Development for the Treatment of Autoimmune Diseases
Christie Fanton¹, Neha Dixit ¹, Suresh Siddhanti ¹, Lin Lu ¹, Daniel Dickerson ², Brian Kotzin ¹ and Jonathan Zalevsky ¹, ¹Nektar Therapeutics, San Francisco, ²PRA Health Sciences, Lenexa
Background/Purpose: Regulatory T cell (Treg) dysfunction and impaired IL-2 production have been implicated as key immunological defects in multiple autoimmune diseases. Enhanced sensitivity of Tregs…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].